Nemesis Bioscience Ltd announced today that it had appointed Dr Yoshinori Yamano to its board as a non-executive director.
Dr Yamano is currently Chief Scientific Officer for Infectious Diseases at Shionogi & Co., Ltd. and has held several senior management positions at Shionogi since joining the company in 1986. He is an internationally renowned microbiologist and research manager, having most recently driven the discovery and development of cefiderocol – a new antibiotic approved for the treatment of complicated urinary tract infections in patients with limited or no alternative treatment options, for hospital-acquired bacterial pneumonia and for the treatment of infections due to aerobic Gram-negative bacteria in patients with limited treatment options.
Dr Yamano will bring enormous expertise in the clinical development of novel antibacterial drugs to Nemesis’ existing Transmid© development platform.
Transmid Technology© has already proved effective in inactivating the antibiotic resistance genes of bacteria, with in vivo studies demonstrating that resistant bacteria are returned to antibiotic sensitivity. Nemesis’ breakthrough technology has important potential for wider commercialisation as it can also be applied to the inactivation of bacterial virulence factors as well as for biosynthetic and industrial microbiology applications.
Commenting on the announcement Dr Frank Massam, CEO of Nemesis said, “We are honoured by Dr Yamano’s decision to join the board of Nemesis Bioscience as a non-executive director. It is hard to overstate the level of expertise in the discovery and development of antibacterial drugs which he will bring to the company in this new role. We look forward with excitement to working with him to bring our Transmid Technology© to market and to making our technology widely available for the treatment and prevention of antibiotic-resistant infections”
Dr Yamano commented, “I am very pleased to join the board of Nemesis Bioscience as a non-executive director. The innovative approach is essential to tackle AMR infection in the world. I would like to contribute in this role to the success of this important Transmid Technology©.”